Sanofi and Wellstat team up to work on investigational drug
GAITHERSBURG, Md. Sanofi-Aventis and Wellstat Therapeutics Corp. will work together on an investigational drug for treating Type 2 diabetes, the two companies announced.
Under an agreement between the two companies, Sanofi will receive an exclusive worldwide license for the drug, currently called PN2034, and related compounds, while Wellstat will receive an upfront cash payment and milestone payments totaling up to $350 million, as well as royalties.
“Sanofi-Aventis has a profound understanding of metabolic diseases, including diabetes, and their markets,” Wellstat VP licensing and business development David Wohlstadter said in a statement. “The capabilities that Sanofi-Aventis brings to the continuing development of PN2034 promise to maximize the significant potential of this compound for patients needing new therapeutic options.”
FDA using pharmaceutical market research to track influenza treatment
BRIDGEWATER, N.J. The Food and Drug Administration is using prescription data from a pharmaceutical market research firm to track treatment of A-H1N1 and other influenza viruses.
Wolters Kluwer Pharma Solutions announced Wednesday that the FDA would use its weekly updates to see who was using the four most popular oral antiviral drugs — Roche’s Tamiflu (oseltamivir), GlaxoSmithKline’s Relenza (zanamivir), Forest Labs’ Flumadine (rimantadine) and Endo Pharmaceuticals’ Symmetrel (amantadine), the latter two of which are available in generic form — and identify clusters where large numbers of people use them.
“The FDA is using our prescription data as a means of tracking the treatment of populations affected by flu outbreaks, including the H1N1 virus, and the specific medications being used to treat them,” Wolters Kluwer Pharma Solutions CEO Mark Spiers said in a statement. “The data are typically not more than five days old upon delivery.”
NACDS pharmacy affairs chief Rosato honored as distinguished Temple alumna
ALEXANDRIA, Va. Edith Rosato, SVP pharmacy affairs for the National Association of Chain Drug Stores and president of the NACDS Foundation, was honored Friday for her achievements and leadership in the pharmacy profession.
The honor came from Rosato’s alma mater, Temple University, which named the pharmacy veteran with the distinguished 2009 Gallery of Success Award. Rosato is a 1982 graduate of the Temple University School of Pharmacy.
Each of Temple’s 17 schools and colleges annually honor two alumni who serve as inspirations to the next generation of Temple graduates. “Ms. Rosato brings over 30 years of leadership and experience in the pharmaceutical industry to her position” at NACDS, Temple noted in announcing the award. “As a registered pharmacist, she has a deep commitment to the advancement of community pharmacy and advocates for the important and integral role for pharmacists in the delivery of quality health care to patients.”
Gallery of Success award recipients, including Rosato, will have their photos and biographies displayed on the Temple University campus in Philadelphia throughout the academic year.
“Edith’s alma mater should be commended for making an outstanding selection for this high honor,” noted NACDS president and CEO Steve Anderson. “Everyone at NACDS congratulates her on her achievements and looks forward to her continued success.”